Neurocrine Biosciences Inc (NBIX)

42.77
1.10 2.60
NASDAQ : Health Care
Prev Close 43.90
Open 43.85
Day Low/High 42.76 / 44.34
52 Wk Low/High 31.25 / 58.46
Volume 597.35K
Avg Volume 1.11M
Exchange NASDAQ
Shares Outstanding 87.11M
Market Cap 3.84B
EPS -1.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Premarket Biotech Movers: Neurocrine Biosciences, Aralez Pharmaceuticals, Qiagen

Premarket Biotech Movers: Neurocrine Biosciences, Aralez Pharmaceuticals, Qiagen

Neurocrine Biosciences, Aralez Pharmaceuticals and Qiagen were among the biotech stock movers in premarket trading on Friday.

Analysts' Actions -- Ford, Intel, Whirlpool, Wynn and More

Analysts' Actions -- Ford, Intel, Whirlpool, Wynn and More

Here are Friday's top research calls, including upgrades for Ford, Intel and Wynn Resorts, and a downgrade for Whirlpool.

Neurocrine Drug Fails to Reduce Tic Severity in Tourette Syndrome Patients

Neurocrine Drug Fails to Reduce Tic Severity in Tourette Syndrome Patients

The same Neurocrine drug, valbenazine, is currently under review at the FDA as a treatment for the movement disorder tardive dyskinesia.

Neurocrine Announces Completion Of Phase II Clinical Study Of VMAT2 Inhibitor INGREZZA™ (valbenazine) In Adults With Tourette Syndrome

Neurocrine Announces Completion Of Phase II Clinical Study Of VMAT2 Inhibitor INGREZZA™ (valbenazine) In Adults With Tourette Syndrome

Eight Week Study Assessed Safety, Tolerability and Efficacy in 124 Adult Subjects

Neurocrine Provides Update On FDA Advisory Committee For INGREZZA™ (valbenazine) For The Treatment Of Tardive Dyskinesia

Neurocrine Provides Update On FDA Advisory Committee For INGREZZA™ (valbenazine) For The Treatment Of Tardive Dyskinesia

Company to Host Conference Call and Webcast Today, January 5th at 4:30pm ET / 1:30pm PT

Neurocrine Biosciences To Present At The 35th Annual J.P. Morgan Healthcare Conference

Neurocrine Biosciences To Present At The 35th Annual J.P. Morgan Healthcare Conference

Live Audio Webcast will be on January 9, 2017

17 Thoughts on Biotech Stocks to Kick Off 2017

17 Thoughts on Biotech Stocks to Kick Off 2017

Adam Feuerstein compiles a list of questions, thoughts, declarations, catalysts and observations about biotech stocks to help investors prepare for the year ahead.

Neurocrine Biosciences Announces Chief Financial Officer Timothy P. Coughlin To Step Down

Neurocrine Biosciences Announces Chief Financial Officer Timothy P. Coughlin To Step Down

Will Continue to Support Company Over Extended Transition Period Through End of 2017

Neurocrine Biosciences To Present At The 28th Annual Piper Jaffray Healthcare Conference

Neurocrine Biosciences To Present At The 28th Annual Piper Jaffray Healthcare Conference

Live Audio Webcast will be on November 30, 2016

Neurocrine Biosciences To Present At The Jefferies 2016 London Healthcare Conference

Neurocrine Biosciences To Present At The Jefferies 2016 London Healthcare Conference

Live Audio Webcast will be on November 16, 2016

Neurocrine Biosciences To Present At The Credit Suisse 25th Annual Healthcare Conference

Neurocrine Biosciences To Present At The Credit Suisse 25th Annual Healthcare Conference

Live Audio Webcast will be on November 7, 2016

Neurocrine Biosciences Announces Conference Call And Webcast To Report Third Quarter 2016 Results

Neurocrine Biosciences Announces Conference Call And Webcast To Report Third Quarter 2016 Results

Conference Call and Webcast Scheduled For Wednesday, November 2, 2016

AbbVie Announces Positive Pivotal Phase 3 Data Demonstrating Investigational Medicine Elagolix Reduces Menstrual And Non-Menstrual Pelvic Pain Associated With Endometriosis At The American Society For Reproductive Medicine Scientific Congress

AbbVie Announces Positive Pivotal Phase 3 Data Demonstrating Investigational Medicine Elagolix Reduces Menstrual And Non-Menstrual Pelvic Pain Associated With Endometriosis At The American Society For Reproductive Medicine Scientific Congress

- Elagolix shows superiority compared to placebo in reducing daily menstrual and non-menstrual pelvic pain associated with endometriosis

These 5 Biotech Stocks Are Ready for a Volatility Break

These 5 Biotech Stocks Are Ready for a Volatility Break

The squeeze is on these stocks, and they are poised for volatile moves.

Neurocrine Biosciences To Present At The Morgan Stanley Global Healthcare Conference

Neurocrine Biosciences To Present At The Morgan Stanley Global Healthcare Conference

Live Audio Webcast will be on September 13, 2016

Neurocrine Biosciences to Present at the Baird 2016 Healthcare Conference

Neurocrine Biosciences to Present at the Baird 2016 Healthcare Conference

Live Audio Webcast will be on September 7, 2016

Neurocrine Announces Initiation Of A Long-Term Phase II Clinical Study Of VMAT2 Inhibitor Valbenazine In Tourette Syndrome

Neurocrine Announces Initiation Of A Long-Term Phase II Clinical Study Of VMAT2 Inhibitor Valbenazine In Tourette Syndrome

Six Month Open Label Safety and Tolerability Study of Valbenazine

Short Interest In Neurocrine Biosciences Jumps 14%

Short Interest In Neurocrine Biosciences Jumps 14%

The most recent short interest data has been released for the 07/15/2016 settlement date, which shows a 606,250 share increase in total short interest for Neurocrine Biosciences, Inc. , to 4,930,434, an increase of 14.02% since 06/30/2016.

Neurocrine Biosciences Announces Conference Call And Webcast To Report Second Quarter 2016 Results

Neurocrine Biosciences Announces Conference Call And Webcast To Report Second Quarter 2016 Results

Conference Call and Webcast Scheduled For Wednesday, August 3, 2016

Bearish Bets: Biotech, Energy and Other Stocks that Look Good to Short

NBIX, ZPIN, VLP, NWLI and INFO were all recently downgraded by TheStreet's Quant Ratings.